Wexler Wallace is investigating claims that certain tenofovir disoproxil fumarate (TDF) drugs used to treat and reduce the risk of getting HIV have serious side effects such as kidney failure, osteoporosis, and broken or brittle bones. If you or a loved one have experienced these side effects while taking Truvada or similar TDF drugs, contact Wexler Wallace for information on filing a Truvada lawsuit.
Only a few decades ago, a diagnosis of HIV was considered a death sentence. Thanks to advancements in medical science, HIV can now be treated and managed like a chronic illness. But while HIV drugs have given patients a new lease on life, the manufacturer of TDF drugs, Gilead Sciences, Inc., are alleged to have known about the serious side effects of Truvada, and delayed putting its safer HIV drugs on the market in order to maximize patent profits on their TDF drugs.
Truvada is the most popular formulation of Gilead’s TDF drugs, which include Atripla, Complera, Stribild, Symfi-Lo, Cimduo, Viread, and others. These drugs are alleged to have serious health risks, including:
- Chronic kidney disease
- Kidney failure
- Decreased bone density (Osteoporosis)
- Bone weakening and fractures
A safer version of tenofovir, known as TAF, was in development for several years before Truvada was even available on the market. But clinical research on TAF was halted—and remained so for over a decade—once Truvada received FDA approval, allowing Gilead to reap the profits of its original patent. This decision may have exposed millions of HIV-positive customers to serious and irreversible health complications.
Get a Free Truvada Lawsuit Case Evaluation
If you or a loved one were taking Truvada or similar TDF drugs and experienced kidney or bone issues, you may qualify for compensation through a Truvada HIV drug lawsuit. Contact Wexler Wallace for a free case evaluation. Our firm is a nationwide leader in dangerous drug and medical device litigation, with experience taking on some of the industry’s biggest and most powerful manufacturers.